Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEND-CRC in Metastatic Colorectal Cancer
NCT07318389Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2026
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bevacizumab, KL-140, panitumumab, FOLFIRI, FOLFOX and 6 more in colorectal cancer (CRC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and Adverse Events at 1 year. Started Apr 2026; status: recruiting.
02
Drugs
bevacizumabKL-140panitumumabFOLFIRIFOLFOX
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07318389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07318389.